Encouraging results have been published for two phase 1/2 COVID-19 vaccine trials, one from the University of Oxford with support from Astra Zeneca, the other from researchers supported by CanSino Biologics in Wuhan, China. Both groups used a virus vector, and both report responses of the vaccine to SARS-CoV-2 by day 28 as well as […]
This article in The Lancet describes the impact of the COVID-19 pandemic on the two-week wait referral for cancer diagnosis in the UK from the results of two modelling studies looking at up to 20 different cancers. The article concludes that patients whose symptoms indicate cancer have been disadvantaged, and some patients will die as […]
Currently, it is difficult for clinicians to decide which patients will respond to immunotherapy and, therefore, what is the best course of treatment for patients with metastatic renal cell carcinoma (RCC). A recent study published in Oncoimmunology describes a combination of two potential biomarkers that may help predict response to immunotherapy for metastatic RCC patients, […]
The results from two studies have been released to show the impact of the COVID-19 pandemic on cancer care in the UK. Data from Cancer Research UK showed a steep rise in the number of people waiting for diagnostic tests, while a study by the Institute for Cancer Research (ICR) published in The Lancet warned that […]
Because so little was known about coronavirus at the start of the pandemic, there was a lot of discussion between healthcare professionals about the best way to manage cancer patients with the threat of infection with the virus. In recent years, immune checkpoint inhibitors have become standard of care for most metastatic renal cell carcinoma […]
In this study carried out at a single hospital 217 cancer patients, who had at least 2 years follow-up data after treatment with immune checkpoint inhibitors (PD-1 or PD-L1), were followed-up long term for adverse events and health-related quality of life (HRQoL). There were 44 patients with renal cell carcinoma (RCC) in the study. Other […]
This article from Oncology Nursing News reports the results of a survey of 95 kidney cancer patients conducted by Kidney Cancer UK in April 2020 about the effect of the COVID-19 pandemic on the care and treatment of kidney cancer patients. Three key messages came out of the survey: Although patients are concerned about COVID-19 […]
This study looked at inflammatory biomarkers in the blood for the diagnosis of non-metastatic renal cell carcinoma (RCC). Inflammation is known to be associated with cancer, and there have been a number of studies that have looked at the relationship between cancer and inflammatory biomarkers. Inflammatory biomarkers such as the neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, lymphocyte/monocyte […]
This meta-analysis of first-line immunotherapy trials was published in the journal Cancers last month. The analysis compares the three active first-line treatment combinations for metastatic renal cell carcinoma (RCC) and provides guidance in the selection of treatment for previously untreated patients. Three combination treatments were compared; pembrolizumab plus axitinib, avelumab plus axitinib and nivolumab plus […]
A study published in European Urology in July looks at the treatment of patients with a specific type of kidney cancer where the cells in the tumours look like the cells of a sarcoma (cancer of connective tissue such as muscles, nerves, fat, blood vessels etc.). This is called sarcomatoid kidney cancer and patients with […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
